SecBot SecBot
8-K ·Filed Jun 10, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001062993-26-003132
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Nasdaq compliance removes near-term delisting risk but does not change INM's weak fundamental outlook, the stock still trades near the $1 threshold with minimal analyst support. Monitor upcoming quarterly results for any revenue or pipeline catalyst that could sustain the bid price above $1.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.51
T+0 close · Jun 10, 2026 · via day close
Latest settled
−11.92%
T+60 · $1.33
Vs SPY
−18.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $1.51entry
  2. T+1 · 5mo ago +4.64%α +2.94% · $1.58
  3. T+5 · 5mo ago −1.99%α −5.42% · $1.48
  4. T+20 · 4mo ago +9.93%α +6.31% · $1.66
  5. T+60 · 2mo ago −11.92%α −18.50% · $1.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice received on March 27, 2026. The company demonstrated a closing bid price at or above $1.00 for 10 consecutive business days through June 2, 2026. This is a procedural compliance update, it removes an immediate delisting overhang but does not change the company's operational or financial trajectory.

Key Facts

  • InMed received a Nasdaq deficiency notice on March 27, 2026 for non-compliance with the $1.00 bid price rule (Rule 5550(a)(2))
  • Nasdaq confirmed compliance on June 3, 2026, based on 10 consecutive business days (May 19–June 2, 2026) with closing bid at or above $1.00
  • The matter is now closed with no further action required by Nasdaq
  • Company has a market cap of ~$4M and analyst consensus is 0% bullish (3 Hold, 4 Sell, 1 Strong Sell)

Financial Impact

No direct financial impact; removal of delisting risk removes a potential liquidity and capital-access overhang

Risk Factors

  • Stock could fall back below $1.00, triggering a new deficiency process
  • No revenue or operational catalyst announced, continued listing remains dependent on share price stability
  • Low market cap and bearish analyst consensus suggest limited institutional support

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062993-26-003132
Exhibit: exhibit99-1.htm0001062993-26-003132
Document: 0001062993-26-003132-index-headers.html0001062993-26-003132
Document: 0001062993-26-003132-index.html0001062993-26-003132
Document: 0001062993-26-003132.txt0001062993-26-003132

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026